The Group A Streptococcal Vaccine Candidate VAX-A1 Protects against Group B Streptococcus Infection via Cross-Reactive IgG Targeting Virulence Factor C5a Peptidase

• Published in: Vaccines (Basel) 2023-12, Vol.11 (12), p.1811
• Main Authors: McCabe, Sinead, Bjånes, Elisabet, Hendriks, Astrid, Wang, Zhen, van Sorge, Nina M, Pill-Pepe, Lucy, Bautista, Leslie, Chu, Ellen, Codée, Jeroen D C, Fairman, Jeff, Kapoor, Neeraj, Uchiyama, Satoshi, Nizet, Victor
• Format: Article
• Language: English
• Subjects: Abnormalities; Animal models; Antibiotics; Antibodies; Antigens; Bacteria; Birth weight; C5a peptidase; Complement component C5a; Cross-protection; Fetuses; group A Streptococcus; group B Streptococcus; Health care; Immunization; Immunoglobulin G; Infant mortality; Low birth weight; Molecular weight; Mortality; Mutagenesis; Neonates; Neurodevelopmental disorders; Neutrophils; Newborn babies; Pathogens; Peptidase; Peptidases; Pregnancy; Premature birth; Product development; Proteins; Risk factors; Sepsis; Streptococcus; Streptococcus agalactiae; Streptococcus infections; Streptococcus pyogenes; vaccine; Vaccines; Virulence; Virulence factors; Womens health
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11121811

Group B ( or GBS) is the leading infectious cause of neonatal mortality, causing roughly 150,000 infant deaths and stillbirths annually across the globe. Approximately 20% of pregnant women are asymptomatically colonized by GBS, which is a major risk factor for severe fetal and neonatal infections as well as preterm birth, low birth weight, and neurodevelopmental abnormalities. Current clinical interventions for GBS infection are limited to antibiotics, and no vaccine is available. We previously described VAX-A1 as a highly effective conjugate vaccine against group A that is formulated with three antigens, SpyAD, streptolysin O, and C5a peptidase (ScpA). ScpA is a surface-expressed, well-characterized GAS virulence factor that shares nearly identical sequences with the lesser studied GBS homolog ScpB. Here, we show that GBS C5a peptidase ScpB cleaves human complement factor C5a and contributes to disease severity in the murine models of pneumonia and sepsis. Furthermore, antibodies elicited by GAS C5a peptidase bind to GBS in an ScpB-dependent manner, and VAX-A1 immunization protects mice against lethal GBS heterologous challenge. These findings support the contribution of ScpB to GBS virulence and underscore the importance of choosing vaccine antigens; a universal GAS vaccine such as VAX-A1 whose formulation includes GAS C5a peptidase may have additional benefits through some measure of cross-protection against GBS infections.